Atıf Formatları
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

A. ÇİLLİ Et Al. , "Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis," PULMONARY PHARMACOLOGY & THERAPEUTICS , vol.71, 2021

ÇİLLİ, A. Et Al. 2021. Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis. PULMONARY PHARMACOLOGY & THERAPEUTICS , vol.71 .

ÇİLLİ, A., ÜZER, F., SEVİNÇ, C., COŞKUN, N. F., URSAVAŞ, A., ÖNER, Ş., ... KÖSE, F.(2021). Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis. PULMONARY PHARMACOLOGY & THERAPEUTICS , vol.71.

ÇİLLİ, AYKUT Et Al. "Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis," PULMONARY PHARMACOLOGY & THERAPEUTICS , vol.71, 2021

ÇİLLİ, AYKUT Et Al. "Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis." PULMONARY PHARMACOLOGY & THERAPEUTICS , vol.71, 2021

ÇİLLİ, A. Et Al. (2021) . "Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis." PULMONARY PHARMACOLOGY & THERAPEUTICS , vol.71.

@article{article, author={AYKUT ÇİLLİ Et Al. }, title={Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis}, journal={PULMONARY PHARMACOLOGY & THERAPEUTICS}, year=2021}